Natural history of GATA1 mutations in Down syndrome

Blood

Volumn 103, Issue 7, 2004, Pages 2480-2489

  Ahmed, Momin ^c   Sternberg, Alexander ^c   Hall, Georgina ^c   Thomas, Angela ^c   Smith, Owen ^c   O'Marcaigh, Aengus ^c   Wynn, Robert ^c   Stevens, Richard ^c   Addison, Michael ^c   King, Derek ^c   Stewart, Barbara ^c   Gibson, Brenda ^c   Roberts, Irene ^b   Vyas, Paresh ^a  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^b HAMMERSMITH HOSPITAL   (United Kingdom)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

TRANSCRIPTION FACTOR GATA 1;

ACUTE MEGAKARYOCYTIC LEUKEMIA; ADULT; ARTICLE; CLINICAL ARTICLE; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE PREDISPOSITION; DNA ISOLATION; DOWN SYNDROME; FEMALE; GENE MUTATION; HUMAN; MALE; MOLECULAR CLONING; MYELOPROLIFERATIVE DISORDER; NUCLEOTIDE SEQUENCE; PATHOGENESIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; UMBILICAL CORD BLOOD;

EID: 12144287045     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2003-10-3383     Document Type: Article

References (38)

1. Lange B. The management of neoplastic disorders of haematopoiesis in children with Down's syndrome. Br J Haematol. 2000;110:512-524.
2. Taub JW, Ravindranath Y. Down syndrome and the transient myeloproliferative disorder: why is it transient? J Pediatr Hematol Oncol. 2002;24:6-8.
3. Zipursky A. Transient leukaemia-a benign form of leukaemia in newborn infants with trisomy 21. Br J Haematol. 2003;120:930-938.
4. Gamis AS Hilden JM. Transient myeloproliferative disorder, a disorder with too few data and many unanswered questions: does it contain an important piece of the puzzle to understanding hematopoiesis and acute myelogenous leukemia? J Pediatr Hematol Oncol. 2002;24:2-5.
5. Zipursky A, Poon A, Doyle J. Leukemia in Down syndrome: a review. Pediatr Hematol Oncol. 1992;9:139-149.
6. Zipursky A, Brown E, Christensen H, Sutherland R, Doyle J. Leukemia and/or myeloproliferative syndrome in neonates with Down syndrome. Semin Perinatol. 1997;21:97-101.
7. Smrcek JM, Baschat AA, Germer U, Gloeckner-Hofmann K, Gembruch U. Fetal hydrops and hepatosplenomegaly in the second half of pregnancy: a sign of myeloproliferative disorder in fetuses with trisomy 21. Ultrasound Obstet Gynecol. 2001;17:403-409.
8. Creutzig U, Ritter J, Vormoor J, et al J. Myelodysplasia and acute myelogenous leukemia in Down's syndrome: a report of 40 children of the AML-BFM Study Group. Leukemia. 1996;10:1677-1686.
9. Lange B, Kobrinsky N, Barnard D, et al. Distinctive demography, biology, and outcome of acute myeloid leukemia and myelodysplastic syndrome in children with Down syndrome: Children's Cancer Group Studies 2861 and 2891. Blood. 1998;91:608-615.
10. Hasle H, Clemmensen IH, Mikkelsen M. Risks of leukaemia and solid tumours in individuals with Down's syndrome. Lancet. 2000;355:165-169.
11. ZipurskyA, Christensen H, De Harven E. Ultrastructural studies of the megakaryoblastic leukemias of Down syndrome. Leuk Lymphoma. 1995;18:341-347.
12. Karandikar NJ, Aquino DB, McKenna RW, Kroft SH. Transient myeloproliferative disorder and acute myeloid leukemia in Down syndrome: an immunophenotypic analysis. Am J Clin Pathol. 2001;116:204-210.
13. Yumura-Yagi K, Hara J, Kurahashi H, et al. Mixed phenotype of blasts in acute megakaryocytic leukaemia and transient abnormal myelopoiesis in Down's syndrome. Br J Haematol. 1992;81:520-525.
14. Girodon F, Favre B, Couillaud G, Carli PM, Parmeland C, Maynadie M. Immunophenotype of a transient myeloproliferative disorder in a newborn with trisomy 21. Cytometry. 2000;42:118-122.
15. Dastugue N, Lafage-Pochitaloff M, Pages MP, et al. Cytogenetic profile of childhood and adult megakaryoblastic leukemia (M7): a study of the Groupe Francais de Cytogenetique Hematologique (GFCH). Blood. 2002;100:618-626.
16. Wechsler J, Greene M, McDevitt MA, et al. Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome. Nat Genet. 2002;32:148-152.
17. Mundschau G, Gurbuxani S, Gamis AS, Greene ME, Arceci RJ, Crispino JD. Mutagenesis of GATA1 is an initiating event in Down syndrome leukemogenesis. Blood. 2003;101:4298-4300.
18. Hitzler JK, Cheung J, Li Y, Scherer SW, Zipursky A. GATA1 A. GATAL mutations in transient leukemia and acute megakaryoblastic leukemia of Down syndrome. Blood. 2003;101:4301-4304.
19. Rainis L, Bercovich D, Strehl S, et al. Mutations in exon 2 of GATA1 are early events in megakaryocytic malignancies associated with trisomy 21. Blood. 2003;102:981-986.
20. Groet J, McElwaine S, Spinelli M, et al. Acquired mutations in GATA1 in neonates with Down's syndrome with transient myeloid disorder. Lancet. 2003;361:1617-1620.
21. Gilliland DG, Griffin JD. The roles of FLT3 in hematopoiesis and leukemia. Blood. 2002;100:1532-1542.
22. Look AT. A leukemogenic twist for GATA1. Nat Genet. 2002;32:83-84.
23. Shivdasani RA, Orkin SH. The transcriptional control of hematopoiesis. Blood. 1996;87:4025-4039.
24. Orkin SH. Diversification of haematopoieic stem cells to specific lineages. Nature Reviews Genetics. 2000;1:57-64.
25. Cantor AB Orkin SH. Hematopoietic development: a balancing act. Curr Opin Genet Dev. 2001;11:513-519.
26. Shivdasani RA, Fujiwara Y, McDevitt MA, Orkin SH. A lineage-selective knockout establishes the critical role of transcription factor GATA-1 in megakaryocyte growth and platelet development. EMBO J. 1997;16:3965-3973.
27. Vyas P, Ault K, Jackson CW, Orkin SH, Shivdasani RA. Consequences of GATA-1 deficiency in megakaryocytes and platelets. Blood. 1999;93:2867-2875.
28. Nichols KE, Crispino JD Poncz M, et al. Familial dyserythropoietic anaemia and thrombocytopenia due to an inherited mutation in GATA1, Nat Genet. 2000;24:266-270.
29. Freson K, Devriendt K, Matthijs G, et al. Platelet characteristics in patients with X-linked macrothrombocytopenia because of a novel GATA1 mutation. Blood. 2001;98:85-92.
30. Freson K, Matthijs G, Thys C, et al. Different substitutions at residue D218 of the X-linked transcription factor GATA1 lead to altered clinical severity of macrothrombocytopenia and anemia and are associated with variable skewed X inactivation. Hum Mol Genet. 2002;11:147-152.
31. Yu C, Niakan KK, Matsushita M, Stamatoyannopoulos G, Orkin SH, Raskind WH. X-linked thrombocytopenia with thalassemia from a mutation in the amino finger of GATA-1 affecting DNA binding rather than FOG-1 interaction. Blood. 2002;100:2040-2045.
32. Mehaffey MG, Newton AL, Gandhi MJ, Crossley M, Drachman JG. X-linked thrombocytopenia caused by a novel mutation of GATA-1. Blood. 2001;98:2681-2688.
33. Gale K, Ford A, Repp R, et al. Backtracking leukemia to birth: identification of clonotypic gene fusion sequences in neonatal blood spots. Proc Natl Acad Sci USA. 1997;94:13950-13954.
34. Wiemels JL, Cazzaniga G, Daniotti M, et al. Prenatal origin of acute lymphoblastic leukaemia in children. Lancet. 1999;354:1499-1503.
35. Wiemels J, Xiao Z, Buffler P, et al. In utero origin of t(8;21) AML1-ETO translocations in childhood acute myeloid leukemia. Blood. 2002;99:3801-3805.
36. Mori H, Colman S, Xiao Z, et al. Chromosome translocations and covert leukemic clones are generated during normal fetal development. Proc Natl Acad Sci U S A. 2002;99:8242-8247.
37. Fabia J, Drolette M. Malformations and leukemia in children with Down's syndrome. Pediatrics. 1970;45:60-70.
38. Satge D, Sommelet D, GeneixA, Nishi M, Malet P, Vekemans M. A tumor profile in Down syndrome. Am J Med Genet. 1998;78:207-216.